Taflin, Helena
Odin, Elisabeth
Carlsson, Göran
Tell, Roger
Gustavsson, Bengt
Wettergren, Yvonne http://orcid.org/0000-0001-8660-7169
Funding for this research was provided by:
The Swedish Cancer Society (CAN 2015/499)
The King Gustav V Jubilee Clinic Foundation for Cancer Research (2016:70)
The Swedish state under the LUA/ALF agreement (ALFGBG-426941)
The IngaBritt and Arne Lundberg Foundation (335/07)
Isofol Medical AB
University of Gothenburg
Article History
Received: 14 July 2020
Accepted: 6 October 2020
First Online: 24 October 2020
Compliance with ethical standards
:
: RT is an employee of Isofol. BG and EO are stockholders of Isofol. BG and HT are immediate family members. Other authors declare no competing interests.
: The study was done in accordance with the Declaration of Helsinki and adhered to the ICH Good Clinical Practice Guidelines. The protocol complied with local regulations and was approved by the Institutional Review Board, the Swedish National Competent Authority, Medical Products Agency (MPA), and the Regional Ethics Committee of Gothenburg (395–16/501–14 and 2019–06166).
: All included patients provided written informed consent to participate.